Abstract 315P
Background
Based on PRIMA and PRIME, Niraparib is approved by FDA and NMPA for first-line maintenance of OC regardless of biomarker status. Niraparib is widely used in China, while its efficacy and safety in real world remains to be verified. The purpose of this study was to evaluate the efficacy and safety of niraparib as maintenance in newly diagnosed advanced OC.
Methods
We retrospectively collected patients with pathologically confirmed diagnosis of OC, who received niraparib as first-line maintenance therapy at the Department of Gynecology, Tianjin Cancer Hospital between January 2021 and December 2022. Demographics, baseline characteristics, clinical outcomes and adverse events were collected. The history of niraparib use, including the time from the end of chemotherapy to the start of maintenance therapy, the starting dose, and the stable dose used after 3 months, were also collected.
Results
102 patients were enrolled. The median age was 58 years and 84.3% were FIGO stage III/IV. 18.6% BRCAmut, 58.8% BRCAwt and 22.5% BRCAunkown, while 36.3% HRD deficient, 12.7% HRD proficient and 51% HRD unkown. 53.9% received NACT, 76.5% were R0 after surgery and 62.7% were CR after chemotherapy. Median follow-up was 10.5m. In the ITT population, the mPFS was not reached, with a 24-month PFS rate of 52.5%. The mPFS of BRCAmut, BRCAwt, and BRCAunknown was not reached, 14.4 and 14.6m, respectively. The 24-month PFS rates were 90%, 48.4% and 37.9%, respectively. The mPFS of HRD deficient and HRD proficient were both not reached. 84.3% of patients experienced any grade TEAEs, while 17.6% experienced TEAEs of grade ≥3. TEAEs leading to treatment interruption was 36.3%, leading to dose reduction was 29.4%, leading to discontinuation was 0.98%. The most common hematological TEAEs were platelet count decreased (28.4%) while grade ≥3 TEAEs was 5.9%, white blood cell count decreased (20.6%) and neutrophil count decreased (26.5%). Non-hematologic TEAEs were nausea (31.4%), fatigue (30.4%) and insomnia (21.6%).
Conclusions
In the real world, niraparib maintenance in newly diagnosed advanced OC is effective and safe, which was consistent with previous RCT. More clinical related factors affecting prognosis will be further explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Committee of Gynecological Oncology, Tianjin anti-cancer association.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract